QNCX (STOCKS)
Quince Therapeutics, Inc. Common Stock
$0.930100
-0.016900 (-1.78%)
Prev close: $0.947000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Dirk Thye
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $15.22M
- Employees
- 36
- P/E (TTM)
- -0.10
- P/B (TTM)
- 0.82
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
5
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$2.88 | $-2.61 | +5.4912 | +210.29% |
|
Dec 2025 (Q4)
|
$-7.10 | $-1.93 | -5.1742 | -268.68% |
|
Sep 2025 (Q3)
|
$-2.50 | $-2.21 | -0.2927 | -13.26% |
|
Jun 2025 (Q2)
|
$-2.30 | $-2.57 | +0.2670 | +10.40% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $57.80M |
| Depreciation and Amortization | $146.00K |
| Research and Development | $34.08M |
| Other Operating Expenses | $23.64M |
| Operating Income/Loss | -$57.80M |
| Income/Loss From Continuing Operations After Tax | -$38.42M |
| Income/Loss From Continuing Operations Before Tax | -$40.60M |
| Income Tax Expense/Benefit | -$2.17M |
| Net Income/Loss | -$35.21M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$2.17M |
| Net Income/Loss Attributable To Parent | -$33.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$36.16M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $6.24M |
| Preferred Stock Dividends And Other Adjustments | $3.12M |
| Basic Earnings Per Share | $2.25 |
| Diluted Earnings Per Share | $1.53 |
| Basic Average Shares | 111,620,468 |
| Diluted Average Shares | 111,690,555 |
| Assets | $26.62M |
| Current Assets | $25.58M |
| Cash | $18.20M |
| Prepaid Expenses | $431.00K |
| Other Current Assets | $6.95M |
| Noncurrent Assets | $1.04M |
| Fixed Assets | $550.00K |
| Intangible Assets | $0.00 |
| Other Non-current Assets | $493.00K |
| Liabilities | $10.95M |
| Current Liabilities | $8.77M |
| Accounts Payable | $5.39M |
| Other Current Liabilities | $3.38M |
| Noncurrent Liabilities | $2.18M |
| Equity | $15.67M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $15.67M |
| Liabilities And Equity | $26.62M |
| Net Cash Flow From Operating Activities | -$39.45M |
| Net Cash Flow From Operating Activities, Continuing | -$39.45M |
| Net Cash Flow From Investing Activities | $24.33M |
| Net Cash Flow From Investing Activities, Continuing | $24.33M |
| Net Cash Flow From Financing Activities | $27.27M |
| Net Cash Flow From Financing Activities, Continuing | $27.27M |
| Exchange Gains/Losses | -$1.75M |
| Net Cash Flow | $10.39M |
| Net Cash Flow, Continuing | $12.14M |
| Comprehensive Income/Loss | -$30.38M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$30.38M |
| Other Comprehensive Income/Loss | $4.83M |